1. Introduction {#s0005}
===============

The use of mesoporous silicas (MS) in amorphous drug delivery systems is gaining increasing interest in the pharmaceutical field due to their ability to stabilize the amorphous form of a drug ([@b0105], [@b0100], [@b0110], [@b0065], [@b0050], [@b0055]). Several studies have also shown that drug-loaded MS systems not only have an increased *in vitro* dissolution rate and apparent solubility compared to the crystalline drug alone, but the *in vivo* performance may also be improved ([@b0025], [@b0080], [@b0085], [@b0035], [@b0075]).

Due to their small pores (2--50 nm), MS have large specific surface areas (often greater than 300 m^2^/g), which offer significant additional surface free energy. Therefore, adsorption of drugs on the surface of an MS may allow the system to progress to a lower free energy state, thus, stabilizing the amorphous drug ([@b0015], [@b0085]). Furthermore, if the pore diameter is smaller than the critical crystal nuclei, the MS may also prevent crystallization of the amorphous form through spatial confinement ([@b0010], [@b0100], [@b0090], [@b0115]). Hence, two mechanisms have been proposed for amorphous stabilization: I) non-covalent interactions (e.g. hydrogen bonding) between the drug molecules, and the MS surface II) spatial separation/confinement of the drug in MS pores. For these mechanisms, the loading capacity can be defined as I) a drug monomolecular layer covering the surface of the MS, i.e. monomolecular loading capacity (MLC), and II) filling the pores of the MS, i.e. pore filling capacity (PFC). From these two definitions, it is clear that the surface area and pore volume of the MS will have a significant influence on the drug loading capacities. The influence of these two MS properties on the drug loading capacity has been reported previously, but the results are inconclusive. For example, [@b0095] showed that the loading capacity of captopril increased with increasing MS surface area, while [@b0120] showed that the loading capacity of telmisartan increased with increasing MS pore volume. Another major drawback is that the drug loading capacity is inconsistently reported even for the same drug-MS system ([@b0020], [@b0070], [@b0060]). The reason for this could be the use of different loading techniques ([@b0090], [@b0005]). For example, [@b0005] showed that the loading capacity of fenofibrate in SBA-15 was higher when using melt-fusion compared to the solvent impregnation and [@b0070] showed that the loading capacity of indomethacin in Syloid 244 FP was significantly lower when using solvent immersion compared to rotary evaporation and fluid bed. Finally, [@b0040] demonstrated that solvent impregnation caused fenofibrate to accumulate outside the pores of the MS, which resulted in crystallization.

To overcome the aforementioned inconsistencies regarding the drug loading capacity determinations, [@b0030] recently introduced a differential scanning calorimetry (DSC)-based method to determine the MLC for drugs with good glass-forming ability. Using the proposed method, it is possible to determine the true maximum MLC independent of loading technique. Furthermore, the study showed that drug loading below the experimentally determined MLC resulted in thermodynamically stable amorphous systems.

Thus, using this method, the present study aimed to systematically determine the influence of surface area, pore size, and pore volume of the MS on the drug loading capacities (MLC and PFC). For this purpose, the MLC and PFC of three model drugs celecoxib (CCX), cinnarizine (CIN), and paracetamol (PAR) in five different MS (Sylysia®) grades were determined. All the model drugs were good glass-formers and the Sylysia® grades all had identical chemical composition, but varying surface area, pore size, and pore volume. Thus, any non-covalent interactions between the drug molecules and the MS surface will be identical between grades, which is a prerequisite to enable this comparative study. The experimental monomolecular loading capacities (xMLC) were compared to the theoretical loading capacities (tMLC and tPFC), calculated based on the surface area and amorphous density of the drugs and surface area and pore volume of the MS.

2. Experimental section {#s0010}
=======================

2.1. Materials {#s0015}
--------------

Celecoxib (CCX, *M*~w~ = 381.4 g/mol) was purchased from Dr. Reddy's (Hyderabad, India), cinnarizine (CIN, *M*~w~ = 368.5 g/mol) was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA) and paracetamol (PAR, *M*~w~ = 151.2 g/mol) was purchased from Fagron (Rotterdam, The Netherlands). The different MS grades (Sylysia® SY240, SY350, SY430, SY550, and SY730) were kindly gifted by Fuji Silysia Chemical Ltd (Kasugai Aichi, Japan). The textural properties of SY240, SY350, SY430, SY550, and SY730 are listed in [Table 1](#t0005){ref-type="table"} and the physico-chemical properties of the CCX, CIN, and PAR are summarized in [Table 2](#t0010){ref-type="table"}.Table 1Specification of the different mesoporous silica (MS). The surface area was determined using nitrogen adsorption and average pore volume and diameter were provided by Fuji Silysia Chemical Ltd (Kasugai Aichi, Japan).MS gradeSY240SY350SY430SY550SY730Surface area (m^2^/g)272268559634682Pore diameter (nm)2421177.02.5Pore volume (cm^3^/g)1.801.601.250.800.44Table 2Physico-chemical properties of the model compounds celecoxib (CCX), cinnarizine (CIN), and paracetamol (PAR). Glass transition temperature (*T*~g~), change in heat capacity (△*C*~p~), melting temperature (*T*~m~), and amorphous density were determined using DSC and minimal projection area was determined using MarvinSketch 18.10 from Chemaxon (Budapest, Hungary).Model compoundCCXCINPAR*T*~g~ (°C)59.28.024.3△*C*~p~ (J/g·°C)0.4810.6120.692*T*~m~ (°C)164.0119.4157.0Amorphous density (g/cm^3^)1.351.221.06*M*~w~ (g/mol)381.4368.5151.2Min. projection area (nm^2^)0.570.630.21

2.2. Nitrogen adsorption {#s0020}
------------------------

The surface areas of the different MS grades were determined by nitrogen adsorption at −196 °C using a TriStar 3020 from Micrometrics Instrument Corp. (Norcross, GE, USA). Sample sizes were in the range of 24--70 g and all samples were degassed at 60 °C for 24 h prior to analysis under 1.5 bar nitrogen gas purge. The Brunauer-Emmet-Teller (BET) specific surface areas were extracted from single measurements using the TriStar II software (version 3.02) at relative pressure P/P~0~ = 0.30 and were similar to the surface areas provided by the supplier.

2.3. Helium pycnometry {#s0025}
----------------------

The amorphous densities of the model drugs were determined using an AccuPyc 1330 helium pycnometer from Micromeritics Instruments Corp (Norcross, GA, USA). The amorphous drugs were prepared by melting samples of ∼2 g in an electrical oven at 5 °C above their melting point (*T*~m~) for 5 min and subsequent quench cooling by removing the samples from the oven. Prior to the density measurements, the samples were gently ground and accurately weighed into an aluminum sample holder and their amorphicity confirmed using X-ray powder diffraction (data not shown). The samples were purged with 19.5 psig dry helium in the pycnometer to determine the amorphous densities. The reported results were averages of 10 consecutive measurements.

2.4. Monomolecular loading capacity determinations {#s0030}
--------------------------------------------------

The experimental monomolecular loading capacity (xMLC) was determined using the heat-cool-heat method proposed by [@b0030] Approximately 200 mg of physical mixtures of drug and MS with a drug fraction ranging from 50 to 100 wt% were prepared by gentle mixing using mortar and pestle. Samples of 2--4 mg were then analyzed in a DSC Q2000 from TA Instruments Inc. (New Castle, DE, USA). Initially, the samples were annealed at ∼10 °C above the *T*~m~ of the respective drug for 5 min, followed by a rapid cooling to ∼40 °C below the glass transition temperature (*T*~g~) of the drug. After quenching, the samples were heated at a rate of 20 °C/min to determine the heat capacity (Δ*C*~p~) over the *T*~g~. The samples were run in duplicate and analyzed using the TRIOS software (version 4.3.0.38). A linear fitting of the determined △*C*~p~ as a function of drug fraction (wt%) was performed in order to determine the xMLC as X-intercept (zero △*C*~p~). A 95% prediction interval was determined as the upper- and lower limits of the X-intercept considering each replicate of △*C*~p~ as an individual data point ([@b0030]).

The reported *T*~m~ of the drugs were determined as onset temperature via the TRIOS software for the pure model drug (100 wt%). Thermogravimetric analysis (Discovery TGA, TA Instruments Inc., New Castle, DE, USA) showed that there was no thermal degradation under the thermal conditions applied during the DSC measurements.

3. Results and discussion {#s0035}
=========================

An example of the △C~p~ extrapolation for CCX-SY350 is shown in [Fig. 1](#f0005){ref-type="fig"}. For this system, the xMLC (X-intercept of the extrapolated function) was found to be 24.3 wt%. The determined xMLC including the 95% prediction interval for the three model drugs in the five different MS grades are summarized in [Table 3](#t0015){ref-type="table"}. All systems demonstrated a good linear relationship between drug fraction and △*C*~p~ with correlation coefficients (*r*^2^) from 0.972 to 0.995.Fig. 1Heat capacity (△*C*~p~) plotted as a function of drug fraction for CCX-SY350 after the heat-cool-heat cycle in the DSC. The data is extrapolated to zero △*C*~p~ through linear extrapolation (solid line, *r*^2^ = 0.995) including the 95% confidence interval (dashed lines).Table 3Experimentally determined monomolecular loading capacities (xMLC) for CCX, CIN, and PAR in the different MS grades. The 95% prediction interval is given in brackets.SY240SY350SY430SY550SY730xMLC (wt%)CCX23.4 (20.0--26.4)24.3 (20.7--27.5)34.0 (30.3--37.3)36.9 (32.7--40.4)35.8 (31.8--39.3)CIN21.2 (15.6--25.9)24.3 (20.5--27.7)33.8 (30.8--36.6)37.0 (33.8--39.7)32.9 (28.3--36.7)PAR24.4 (17.2--30.2)30.2 (27.4--32.8)37.3 (31.6--41.8)39.6 (34.8--43.5)28.8 (23.4--33.3)

Comparing the xMLC values for CCX in the different MS grades, it is evident that the xMLC for CCX-SY240 was similar to that obtained for CCX-SY350 (23.4 and 24.3 wt%, respectively). Given that SY240 and SY350 provide a similar surface area available for adsorption (271 and 267 m^2^/g, respectively) this observation was somewhat expected. Furthermore, the increase in surface area between SY350 and SY430 (267 and 559 m^2^/g, respectively) also resulted in an increase in the xMLC from 24.3 to 34.0 wt%. However, the increase in surface area between SY550 and SY730 (which had the largest surface area of 681 m^2^/g), did not result in an increase in the xMLC.

The CIN systems generally displayed the same trend as observed for CCX with similar xMLC for CIN-SY240 and CIN-SY350 (21.2 and 24.3 wt%, respectively). The deviation of the xMLC values can be explained by the relatively large prediction interval for both systems; hence, the difference between the two means is not statistically significant. For CIN-SY350 and CIN-SY430, the larger MS surface area also resulted in an increase in xMLC from 24.3 to 33.8 wt%, respectively. However, interestingly, the xMLC for CIN-SY730 did not increase compared to CIN-SY550, but in fact decreased from 37.0 to 32.9 wt% despite the larger available surface area of SY730.

The PAR systems also displayed the same overall trend as CCX and CIN with a general increase in xMLC with increasing MS surface area from 24.4 to 39.6 wt% for PAR-SY240 and PAR-SY550, respectively. In accordance with the observations for CIN, a significant decrease in xMLC for PAR-SY730 compared to PAR-SY550 was observed (39.6 and 28.8 wt%, respectively). Furthermore, the xMLC obtained for PAR in all MS grades (except SY730) were higher than those obtained for CCX and CIN, which yielded similar xMLC. This can be explained by comparing the molecular size and thus, surface area of the three model drugs (see [Table 2](#t0010){ref-type="table"}). As the molecular surface area of PAR is smaller compared to CCX and CIN, it also occupies a smaller area on the MS surface and therefore, the xMLC obtained for the PAR systems should also be higher in theory. Consequently, these findings strongly indicate that the thermoanalytical method proposed by [@b0030] indeed is able to determine the MLC of drugs with good glass-forming ability in MS.

To elucidate the mechanism responsible for the deviation of the xMLC for the SY730 systems, a theoretical estimation of the MLCs was determined (tMLC). By assuming that drug molecules are able to cover the entire MS surface, the tMLC of any given system can be calculated from:$$\text{tMLC} = \frac{A_{\text{MS}} \cdot M_{\text{w}{(\text{drug})}}}{A_{\text{drug}} \cdot N_{\text{A}}}$$where *A*~MS~ is the surface area of the respective MS (m^2^/g), *A*~drug~ is the minimal projection area of the respective drug (m^2^/molecule), *N*~A~ is the Avogadro constant (6.022·10^23^ mol^−1^), and *M*~w\ (drug)~ is the molecular weight (g/mol) of the respective drug. Using Eq. [(1)](#e0005){ref-type="disp-formula"}, the tMLC is given as *w*~drug~/*w*~MS~ so to enable a comparison with the xMLC, the tMLC was transformed to wt% i.e. *w*~drug~/(*w*~drug~ + *w*~MS~). Accordingly, the tMLC for all drug-MS systems are listed in [Table 4](#t0020){ref-type="table"} and plotted in [Fig. 2](#f0010){ref-type="fig"} as a function of surface area along with the xMLC ([Table 3](#t0015){ref-type="table"}).Table 4Theoretical monomolecular loading capacity (tMLC) of CCX, CIN, and PAR in the different MS grades. The tMLC are calculated based on Eq. [(1)](#e0005){ref-type="disp-formula"} and transformed to wt%.SY240SY350SY430SY550SY730tMLC (wt%)CCX23.323.038.441.543.2CIN21.020.835.438.340.0PAR24.624.440.243.345.1Fig. 2MLC (in *w*~drug~*/w*~MS~) plotted as a function of MS surface area. The tMLC is plotted as a dashed line and the xMLC (transformed to *w*~drug~*/w*~MS~) is represented as red dots with 95% prediction interval for a) CCX, b) CIN, and c) PAR in the five MS grades. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

As can be seen in [Fig. 2](#f0010){ref-type="fig"}, the tMLC for the three drugs in SY240, SY350, SY430, and SY550 are in good agreement with the xMLC. However, for CCX-SY730, CIN-SY730, and PAR-SY730 the tMLC is 7.4, 7.1, and 16.3 wt% higher than the xMLC, respectively, which is significantly above the 95% confidence intervals of the xMLC (see [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). These findings suggest that a part of the available surface area of SY730 is not accessible for the drug molecules and, hence, results in lower than expected xMLC. This inconsistency could be due to the relatively small average pore size of SY730 of 2.5 nm, which may result in a spatial limitation. For example, some pores may be too narrow to accommodate the molecules to be adsorbed adjacently and other pores may simply be smaller than the drug molecule itself (cf. ∼1 nm). Given that the tMLC (Eq. [(1)](#e0005){ref-type="disp-formula"}) is obtained under the assumption that drug molecules are able to cover the entire MS surface, the spatial limitation is a very plausible explanation to the discrepancy observed between the tMLC and xMLC. Similar findings have been reported in literature, where the drug loading decreased with decreasing pore size despite an increase in surface area ([@b0010], [@b0020], [@b0045]).

Based on these observations, it is evident that the larger surface area and tMLC of SY730 is not reflected in a larger xMLC. However, in this case the pore volume rather than the available surface area may be the limiting factor for the loading capacity for this MS grade. In order to evaluate this, the theoretical pore filling capacities (tPFC) for all the systems were calculated from ([@b0040]):$$\text{tPFC} = \frac{V_{\text{MS}} \cdot \rho_{\text{drug}}}{1 + V_{\text{MS}} \cdot \rho_{\text{drug}}} \cdot 100\text{\%}$$where *V*~MS~ is the pore volume of the MS (cm^3^/g) and *ρ*~drug~ is the amorphous density of the drug (see [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}). The calculated tPFC for all the systems are given in [Table 5](#t0025){ref-type="table"}.Table 5Theoretical pore filling capacity (tPFC) of CCX, CIN, and PAR in the different MS grades.SY240SY350SY430SY550SY730tPFC (wt%)CCX68.470.868.451.937.3CIN68.766.160.449.434.9PAR65.662.957.045.931.8

As can be seen, the tPFC for the SY240, SY350, SY430, and SY550 systems are larger than the tMLC as a result of higher pore volumes. The lower tPFC for the PAR systems compared to CXX and CIN is due to lower amorphous density. Furthermore, it is clear that the tPFC for all the SY730 systems are indeed in good agreement with the xMLC. For CCX-SY730, CIN-SY730, and PAR-SY730 the tPFC are 37.3, 34.9, and 31.8 wt%, which is comparable to the xMLC of 35.8, 32.9, and 28.8 wt%, respectively. Hence, this means that the pores of SY730 are completely filled by drug molecules, which indicates that the drug loading capacity for this MS grade is depending on the density of these drugs rather than the surface area. The good correlation between the tPFC and xMLC for the SY730 suggests that the amorphous density of the drugs is a good approximation for the density of the drug molecules inside the MS, which allows for estimation of tPFC for any given pore volume.

To summarize the role interplay between MS textural properties and their effect on drug loading capacity, a simplistic illustration of the xMLC, tMLC, and tPFC as a function of MS pore volume and surface area is shown in [Fig. 3](#f0015){ref-type="fig"}. As can be seen, the tMLC increases with increasing surface area whereas tPFC decrease as a result of the smaller pore diameter necessary to achieve the higher surface area. The figure can be divided into four zones defined by the tPFC and tMLC lines, which represent four different scenarios. In zone I, the drug fraction is lower than the tMLC and the drug can adsorb monomolecularly to the MS surface. In zone II, the drug fraction is higher than the tMLC and the excess drug will be confined within the pores of the MS. In zone III, the drug fraction is higher than the tPFC and excess drug will be deposited outside the MS pores. The intersection between tMLC and tPFC lines corresponds to a hypothetical situation where the entire surface of MS is covered by monomolecular layer drug and the pores are filled concomitantly. From this point, an increase in surface area (through smaller pore diameter) will not result in an increase of drug loading capacity, but rather a decrease, since the entire surface cannot be monomolecularly covered due to the spatial limitation of the narrow pores. Thus, in zone IV the drug molecules are not able to access the entire available surface area and the drug will be deposited outside the MS pores.Fig. 3xMLC (red dots) plotted as a function of MS pore volume and surface area for a) CCX, b) CIN, and c) PAR. The solid lines represents the tMLC and the dashed lines represents the tPFC. In zone I the drug is monomolecularly adsorbed to the MS surface, in zone II the MS pore is filled with drug and in zone III, the pores are overloaded with drug. Zone IV represents a situation where the MS surface is not accessible for the drug molecules and the pores are overloaded with drug. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

4. Conclusion {#s0040}
=============

In this study, the influence of pore volume and surface area of MS on the MLC was investigated systematically. The findings showed that the xMLC is mainly depending on the minimal projection area of the drug molecule, i.e. the xMLC increase with decreasing drug surface area. In case the MS pores are large enough to accommodate drug-monolayers adsorbed adjacently, a good correlation was obtained between the xMLC and tMLC. However, a decrease in xMLC was observed for the MS grade with the highest surface area, which correlated well with the tPLC rather than the tMLC. This was probably a result of the decreasing pore diameter necessary to accommodate the increasing surface area i.e. if the pore diameter is smaller than the drug molecule, the drug cannot access the available surface area. This means that from a certain point, an increase in MS surface area (through smaller pore diameter) will not result in an increase of drug loading capacity because the entire surface cannot be monomolecularly covered (spatial limitation of the narrow pores). Consequently, for all MS there exists a relationship between surface area and pore volume that will allow for maximum drug loading. With this knowledge, future MS grades may be designed with optimal textural properties for any given drug based on the amorphous density and minimal projection area of the drug molecule.
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